Table 4.
Prognostic impact of Grade 3 and Grade 2b on survival (Cox proportional hazards model)
| Variables | Disease-free survival | Overall survival | ||
|---|---|---|---|---|
| HR | 95 % CI | HR | 95 % CI | |
| Study | ||||
| JBCRG-02 | 2.02 | 0.92–4.11 | 2.80 | 0.91–7.64 |
| JBCRG-03 | 1.29 | 0.75–2.18 | 1.40 | 0.57–3.38 |
| Pathologic response | ||||
| Grade 3 | 0.35** | 0.15–0.75 | 0.15** | 0.02–0.55 |
| Grade 2b | 0.19** | 0–0.32 | 0.15* | 0–0.68 |
| Age | 1.00 | 0.97–1.03 | 0.98 | 0.94–1.03 |
| Tumor size | ||||
| >3 cm | 1.20 | 0.74–1.99 | 2.03 | 0.98–4.54 |
| Nuclear grade | ||||
| Grade 3 | 1.34 | 0.68–2.60 | 1.07 | 0.39–2.81 |
| Nodal status | ||||
| n+ | 2.33** | 1.41–3.89 | 3.06** | 1.48–6.67 |
| Clinical response (CR, PR) | ||||
| After the first half of NAC | 0.77 | 0.45–1.30 | 0.77 | 0.34–1.74 |
| Before surgery | 0.83 | 0.47–1.48 | 0.54 | 0.24–1.23 |
| Subtype | ||||
| Luminal-Her2-positive | 1.68 | 0.62–3.87 | 2.81 | 0.62–9.34 |
| Her2-positive | 1.31 | 0.47–3.07 | 3.32 | 0.88–10.24 |
| Triple negative | 3.19** | 1.70–5.86 | 4.80** | 2.02–11.18 |
* p < 0.05, ** p < 0.01
CI confidence interval, CR complete response, HR hazard ratio, NAC neoadjuvant chemotherapy, PR partial response, SD stable disease, PD progressive disease